Metabolic dysfunction-associated steatotic liver disease (MASLD) is the hepatic manifestation of obesity and insulin resistance and is characterized by excessive lipid accumulation that may progress to steatohepatitis, fibrosis, and cirrhosis. Dysregulated hepatic lipogenesis, circadian disruption, and chronic low-grade inflammation are key mechanisms underlying disease progression. REV-ERB, a circadian nuclear receptor, has emerged as an important regulator of hepatic metabolism by modulating lipid synthesis, inflammation, and fatty acid oxidation. However, whether pharmacological modulation of REV-ERB signaling with SR9009 can potentiate the hepatic adaptations induced by resistance training (RT) in MASLD remains unclear. Here, we investigated the effects of SR9009, administered alone or in combination with RT, on metabolic and hepatic parameters in male mice fed a high-fat diet. SR9009, both alone and combined with RT, attenuated body weight gain, improved glycemic control, and reduced visceral adiposity. In the liver, these interventions decreased lipid accumulation, hepatic triglyceride content, and circulating markers of liver injury, while modulating genes related to lipogenesis, fatty acid oxidation, inflammation, and circadian regulation. SR9009 alone increased the expression of genes involved in hepatic fatty acid oxidation, whereas the combination of SR9009 and RT exerted more pronounced effects on ALT levels and on pathways associated with lipogenesis and inflammation. Consistently, in palmitate-stimulated HepG2 cells, SR9009 reduced lipogenic protein content and lipid droplet accumulation. Collectively, these findings demonstrate that pharmacological modulation of REV-ERB signaling attenuates diet-induced hepatic steatosis and suggest that RT may enhance these protective effects, supporting REV-ERB as a promising therapeutic target for MASLD.